Adverse events328

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 328

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Injection site erythema	General disorders	Tildrakizumab 200 mg (Parts 1, 2 & 3) Wk-28 R	5	527	7
other	Injection site erythema	General disorders	Tildrakizumab 100 mg (Parts 1, 2 & 3)	5	487	5
other	Injection site erythema	General disorders	Placebo (Part 1)	1	156	2
other	Injection site erythema	General disorders	Etanercept 50 mg (Parts 1 & 2)	28	313	98
other	Injection site reaction	General disorders	Tildrakizumab 200 mg (Parts 1, 2 & 3) Wk-28 R	4	527	8
other	Injection site reaction	General disorders	Tildrakizumab 100 mg (Parts 1, 2 & 3)	2	487	2
other	Injection site reaction	General disorders	Placebo (Part 1)	1	156	1
other	Injection site reaction	General disorders	Etanercept 50 mg (Parts 1 & 2)	17	313	54
other	Nasopharyngitis	Infections and infestations	Tildrakizumab 200 mg (Parts 1, 2 & 3) Wk-28 R	119	527	173
other	Nasopharyngitis	Infections and infestations	Tildrakizumab 100 mg (Parts 1, 2 & 3)	112	487	152
other	Nasopharyngitis	Infections and infestations	Placebo (Part 1)	12	156	14
other	Nasopharyngitis	Infections and infestations	Etanercept 50 mg (Parts 1 & 2)	63	313	79
other	Upper respiratory tract infection	Infections and infestations	Tildrakizumab 200 mg (Parts 1, 2 & 3) Wk-28 R	27	527	30
other	Upper respiratory tract infection	Infections and infestations	Tildrakizumab 100 mg (Parts 1, 2 & 3)	15	487	18
other	Upper respiratory tract infection	Infections and infestations	Placebo (Part 1)	1	156	1
other	Upper respiratory tract infection	Infections and infestations	Etanercept 50 mg (Parts 1 & 2)	11	313	14
other	Arthralgia	Musculoskeletal and connective tissue disorders	Tildrakizumab 200 mg (Parts 1, 2 & 3) Wk-28 R	14	527	17
other	Arthralgia	Musculoskeletal and connective tissue disorders	Tildrakizumab 100 mg (Parts 1, 2 & 3)	26	487	30
other	Arthralgia	Musculoskeletal and connective tissue disorders	Placebo (Part 1)	3	156	3
other	Arthralgia	Musculoskeletal and connective tissue disorders	Etanercept 50 mg (Parts 1 & 2)	10	313	13

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01729754/events

API reference For AI assistants

Adverse events328

Sources 3

Read this list from software.